EMA Authorised: Fareston (toremifene) — Orion Corporation

View source ↗

Summary

The European Medicines Agency authorised Fareston (toremifene) by Orion Corporation for breast cancer, with the decision dated 26 July 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• FARESTON (toremifene citrate)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms. MAH: Orion Corporation. Decision date: 26/07/2024